KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Raw Materials (2017 - 2021)

Aquestive Therapeutics has reported Raw Materials over the past 5 years, most recently at $833000.0 for Q1 2021.

  • Quarterly results put Raw Materials at $833000.0 for Q1 2021, down 35.18% from a year ago — trailing twelve months through Mar 2021 was $833000.0 (down 35.18% YoY), and the annual figure for FY2020 was $789000.0, down 36.58%.
  • Raw Materials for Q1 2021 was $833000.0 at Aquestive Therapeutics, up from $789000.0 in the prior quarter.
  • Over the last five years, Raw Materials for AQST hit a ceiling of $1.4 million in Q1 2019 and a floor of $725000.0 in Q4 2017.
  • Median Raw Materials over the past 5 years was $1.2 million (2020), compared with a mean of $1.1 million.
  • Biggest five-year swings in Raw Materials: surged 76.97% in 2018 and later plummeted 36.58% in 2020.
  • Aquestive Therapeutics' Raw Materials stood at $725000.0 in 2017, then soared by 76.97% to $1.3 million in 2018, then dropped by 3.04% to $1.2 million in 2019, then tumbled by 36.58% to $789000.0 in 2020, then grew by 5.58% to $833000.0 in 2021.
  • The last three reported values for Raw Materials were $833000.0 (Q1 2021), $789000.0 (Q4 2020), and $1.2 million (Q3 2020) per Business Quant data.